FIBROBLAST GROWTH FACTOR 21 AS A MARKER OF PREMATURE AGING IN YOUNG AND MIDDLED-AGED MEN WITH TYPE 2 DIABETES


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim. To investigate the impact of fibroblast growth factor 21 (FGF-21) on the severity of androgen deficiency in young and middle-aged men with type 2 diabetes mellitus. Materials and methods. The study comprised 100 men with type 2 diabetes mellitus, cardiovascular multi-morbidity, obesity and androgen deficiency (study group) and 20 healthy men aged 35-50 years. The study group was further divided into two subgroups. Patients of the subgroup 1 received the standard treatment for type 2 diabetes and cardiovascular disease. Patients of the subgroup two were treated with conventional therapy concurrently with testosterone undecanoate. The baseline examination included the following parameters: glycated hemoglobin, total testosterone, prolactin, thyroid stimulating hormone and blood FGF-21. At nine months after the treatment, the blood levels of glycated hemoglobin, FGF21 and testosterone were re-examined. The evaluation of the severity of androgen deficiency was carried out using the ICEF-5 questionnaire and the Aging Males’ Symptoms scale (AMS). Results. In the study group, the mean FGF-21 level was 2.7 times higher, and the total testosterone level was 2-2.5 times lower than in the control group (p<0.05). A negative correlation was found between the blood levels of FGF-21 and total testosterone (r=-0.41, p<0.05). At nine months post treatment, the subgroup with testosterone undecanoate administered as add-on therapy showed a further decrease in FGF-21 levels and improved androgen deficiency symptoms. Discussion. FGF-21 is one of the markers for type 2 diabetes, cardiovascular multi-morbidity, obesity and androgen deficiency. Given the association of FGF-21 with androgen deficiency, it can be assumed that FGF-21 plays a role in premature aging. Treatment of androgen deficiency as add-on therapy to the standard treatment of this category of patients improves their prognosis and the quality of life. Conclusion. Young and middle-aged men with type 2 diabetes should undergo regular screening for androgen deficiency with the purpose of its early diagnosis and timely treatment. The detection of elevated levels of FGF-21 in young and middle-aged men with type 2 diabetes mellitus and cardiovascular multi-morbidity may indicate premature aging and requires preventive measures.

Full Text

Restricted Access

About the authors

E. Yu Zagarskikh

I.I. Mechnikov North-Western State Medical University

Email: zagarsklena@mail.ru
Dr.Med.Sci., Professor at the V.G. Baranova Department of Endocrinology

G. A Proshchai

I.I. Mechnikov North-Western State Medical University

Email: galina.proshchai@mail.ru
Ph.D. Student at the V.G. Baranova Department of Endocrinology

N. V Vorokhobina

I.I. Mechnikov North-Western State Medical University

Email: natvorokh@mail.ru
Dr.Med.Sci., Prof., Head of the V.G. Baranova Department of Endocrinology

References

  1. Verbovoj A.F., Vorozhtsova E.I. The condition of pituitary-gonadal system of men with diabetes mellitus of 2nd type and ischemic heart disease. Medical Almanac. 2012;4:109-112.
  2. Luchytskiy E., Luchytskiy V. Age-related aspects of androgendeficiency and erectile function in males with type 2 diabetes mellitus. Men’s health. 2014;48:154.
  3. Hayek A.A., Khader Y.S., Jafal S., Khawaja N., Robert A.A., Ajlouni K. Prevalence of low testosterone levels in men with type 2 diabetes mellitus: a cross-sectional study. J Fam Community Med. 2013;20:179-186.
  4. Vijayamahantesh N.N., Deepak C.L., Sudeep K., Venkatesha B.M. Prevalence of Low Serum Testosterone among Type 2 Diabetes Mellitus: A Predictor of Micro Vascular Disease. International Journal of Healthcare Sciences. 2015;3(1):406-412.
  5. Bondarenko V.M., Pimanov S.I., Dosta N.I. Correlation of serum testosterone level with the amount of visceral adipose tissue. Bulletin of the Vitebsk State Medical University. 2014;13(1):98-103.
  6. Davidovich I.M., Marenin S.N. Erectile dysfunction, androgenic status and endothelium dependent vasodilatation of penile arteries in young hypertensive patients. Far East Medical Journal. 2013;3:20-
  7. Srikanthan P., Karlamangla A.S. Relative muscle mass is inversely associated with insulin resistance and prediabetes. Findings from the third national health and nutrition examination survey. J Clin Endocrinol Metab. 2011;96:2898-2903.
  8. Frolov D.S., Shustov S.B., Khalimov Yu.Sh. The effect of age-related androgenic deficiency on modifying risk factors in males with ischemic heart disease. Treatment and prevention. 2014;2(10):62-67.
  9. Cheng P., Zhang F., Yu L., Lin X., He L., Li X., Lu X., Yan X., Tan Y., Zhang C. Physiological and Pharmacological Roles of FGF21 in Cardiovascular Diseases. Journal of Diabetes Research. 2016;2016:1-8. doi: 10.1155/2016/1540267.
  10. Phillips G.B., Pinkernell B.H., Jing T.Y. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb. 1994;14:701-706.
  11. Bilezikian J.P. Osteoporosis in men. J Clin Endocnnol Metab. 1999;84:3431-3434.
  12. Lin Z., Wu Z., Yin X., Liu Y., Yan X., Lin S., Xiao J., Wang X., Feng W., Li X. Serum levels of FGF-21 Are Increased in Coronary Heart Disease Patients and Are Independently Associated with Adverse Lipid Profile. PLoS ONE. 2010;5(12):e15534. doi: 10.1371/joumal. pone.0015534.
  13. An S.Y., Lee M.S., Yi S.A., Ha E.S., Han S.J., Kim H.J., Kim D.J., Lee K.W. Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques. Diabetes Research and Clinical Practice. 2012;96(2):196-203. doi: 10.1016/j.diabres.2012.01.004.
  14. Chavez A.O., Molina-Carrion M., Abdul-Ghani M.A., Folli F., Defronzo R.A., Tripathy D. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care. 2009;32(8):1542-46. doi: 10.2337/dc09-0684.
  15. Yang M., Dong J., Liu H., Li L., Yang G. Effects of short-term continuous subcutaneous insulin infusion on fasting plasma fibroblast growth factor-21 levels in patients with newly diagnosed type 2 diabetes mellitus. PLoS ONE. 2011 ;6(10):e26359. doi: 10.1371/journal.pone.0026359.
  16. Dostalova I., Haluzikova D., Haluzik M. Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus. Physiological Research/Academia Scientiarum Bohemoslovaca. 2009;58(1):1-7.
  17. Chow W.S., Xu A., Woo Y.C., Tso A.W., Cheung S.C., Fong C.H., Tse H.F., Chau M.T., Cheung B.M., Lam K.S. Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2013;33(10):2454-2459. Doi: 10.1161/ ATVBAHA.113.301599.
  18. Vasilkova O.N., Mokhort T.V., Pchelin I.Yu., Sharshakova T.M., Zhmailik M.V. Effect of testosterone replacement therapy on quality of life of type 2 diabetes patients and androgen deficiency. Juvenis scientia. 2016;2:56-59.
  19. Krutko V.N., Dontsov V.I., Mamikonova O.A., Pirvu V.V., Rozenblit S.I. Diagnosis of aging and biological age in anti-aging medicine. Medical news. 2015;2(245):25-31

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies